晚期卵巢癌复发低风险人群的治疗选择

参考文献：

1.Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer [published correction appears in N Engl J Med. 2012 Jan 19;366(3):284]. N Engl J Med. 2011;365(26):2484-2496. 2. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.

3. Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681-692.

4. The NCCN ovarian cancer including fallopian tube cancer and primary peritoneal cancer clinical practice guidelines in oncology (version 3. 2024).

5. You B, Sehgal V, Hosmane B, et al. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023;41(1):107-116. 

6. Hardesty M, Krivak C, Wright, G, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab [J]. Gynecologic Oncology: An International Journal, 2022, 166(2):219-229.